Similar to observations in other tumor types where combination treatment with ERK or JNK inhibitors restores chemosensitivity[39], we demonstrate enhanced cytotoxicity of the HepG2 cells with the ATO/sorafenib combination in comparison to ATO alone. This evidence concerns the gene MAPK1 and neoplasm.